Blood pressure increases are associated with weight gain and not antiretroviral regimen or kidney function: a secondary analysis from the ADVANCE trial in South Africa
Journal of the International AIDS Society · 2024-07 · 27 (7)
DOI: 10.1002/jia2.26268 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the International AIDS Society, online erschienen am 08.07.2024. Verfasst von Jennifer Manne-Goehler und 9 weiteren Autor:innen. Beteiligte Einrichtung: Medical Practice Evaluation Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: HIV Infections, Tenofovir, Weight Gain, Hypertension. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, SA MRC, UNITAID, USAID, ViiV Healthcare, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Introduction
Recent evidence has raised questions about whether newer HIV treatment regimens, including dolutegravir (DTG) and tenofovir alafenamide (TAF), are associated with increases in blood pressure (BP).
Methods
We assessed changes in BP by treatment regimen and evaluated the relative contribution of kidney function and weight gain to these changes among participants in the ADVANCE phase‐3 trial clinical trial in South Africa (study dates: January 2017–February 2022). Our primary outcome of interest was a change in systolic BP (SBP) at 96 and 192 weeks, among those not receiving antihypertensive medication. The secondary outcome was treatment‐emergent hypertension at these same time points, defined as BP ≥140/90 mmHg on two occasions, or initiation of antihypertensive medication after week 4 among individuals without hypertension at enrolment. We used linear regression to evaluate the relationship between change in estimated glomerular filtration rate (eGFR) and change in SBP; and Poisson regression to evaluate the relationship between change in eGFR and treatment‐emergent hypertension at each time point. All models were adjusted for age, sex, treatment group and change in body mass index (BMI).
Results
Over 96 weeks, the average changes in SBP were 1.7 mmHg (95% CI: 0.0−3.4), −0.5 mmHg (95% CI: −2.2 to 1.7) and −2.1 mmHg (95% CI: −3.8 to 0.4) in the TAF/emtricitabine (FTC)/DTG, tenofovir disoproxil fumarate (TDF)/FTC/DTG and TDF/FTC/efavirenz (EFV) groups, respectively. This difference was significant for the TAF/FTC/DTG compared to the TDF/FTC/EFV group ( p = 0.002). Over 96 weeks, 18.2% (95% CI: 13.4–22.9), 15.4% (95% CI: 11.0–19.9) and 13.3% (95% CI: 8.9–17.6) of participants developed treatment‐emergent hypertension, respectively. In adjusted models, there was no significant relationship between change in eGFR and either outcome. Change in BMI was significantly associated with an increase in SBP, while age was associated with an increased risk of treatment‐emergent hypertension. Adjustment for BMI also mitigated the unadjusted relationship between HIV treatment regimen and SBP where present.
Conclusions
In the ADVANCE cohort, weight gain and age accounted for increases in BP and risk of treatment‐emergent hypertension. HIV treatment programmes may need to integrate the management of obesity and hypertension into routine care. Clinical Trial Number NCT03122262
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Practice Evaluation Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- MRC/Wits Rural Health and Transitions Research Unit (Agincourt), University of the Witwatersrand, Johannesburg, South Africa.
- Wits Donald Gordon Medical Centre, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
- Wits Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
- Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
ORCID-Profile: Jennifer Manne-Goehler, Alana T Brennan
Förderung
- NIDDK NIH HHS
- SA MRC, UNITAID, USAID, ViiV Healthcare
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Manne-Goehler, J., Fabian, J., Sokhela, S., Akpomiemie, G., Rahim, N., Lalla-Edward, S. T., Brennan, A. T., Siedner, M. J., Hill, A., & Venter, W. D. F. (2024). Blood pressure increases are associated with weight gain and not antiretroviral regimen or kidney function: a secondary analysis from the ADVANCE trial in South Africa. Journal of the International AIDS Society, 27(7). https://doi.org/10.1002/jia2.26268
Vancouver
Manne-Goehler J, Fabian J, Sokhela S, Akpomiemie G, Rahim N, Lalla-Edward ST, et al. Blood pressure increases are associated with weight gain and not antiretroviral regimen or kidney function: a secondary analysis from the ADVANCE trial in South Africa. Journal of the International AIDS Society. 2024;27(7). doi:10.1002/jia2.26268
BibTeX
@article{ManneGoehler2024,
author = {Manne-Goehler, Jennifer and Fabian, June and Sokhela, Simiso and Akpomiemie, Godspower and Rahim, Nicholas and Lalla-Edward, Samanta Tresha and Brennan, Alana T and Siedner, Mark J and Hill, Andrew and Venter, Willem Daniel Francois},
title = {Blood pressure increases are associated with weight gain and not antiretroviral regimen or kidney function: a secondary analysis from the ADVANCE trial in South Africa},
journal = {Journal of the International AIDS Society},
year = {2024},
volume = {27},
number = {7},
doi = {10.1002/jia2.26268}
}
EUVIMED